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de Salud Carlos III, Madrid, SpainAbstractWe aimed to develop a simple prediction score to identify ﬂuconazole non-susceptible (Flu-NS) candidaemia using simple clinical criteria. A
derivation cohort was extracted from the CANDIPOP study, a prospective, multicentre, population-based surveillance programme on
candidaemia conducted in 29 hospitals in Spain from April 2010 to May 2011. The score was validated with an external, multicentre
cohort of adults with candidaemia in six tertiary hospitals in three countries. The prediction score was based on three variables selected
by a logistic regression model together with the severity of disease. In total, 617 and 297 cases of candidaemia were included in the
derivation and validation cohorts, respectively; of these, 134 (21.7%) and 57 (19.2%) were caused by Flu-NS strains. Factors
independently associated with Flu-NS were transplant recipient status (adjusted odds ratio (AOR) 2.13; 95% CI 1.01–4.55; p 0.047),
hospitalization in a unit with a high prevalence (15%) of Flu-NS strains (7.53; 4.68–12.10; p < 0.001), and previous azole therapy for at
least 3 days (2.04; 1.16–3.62; p 0.014). The area under the receiver operating characteristics curve (AUC) was 0.76 (0.72–0.81), and
using 2 points as the Flu-NS prediction score cut-off gave a sensitivity of 82.1%, a speciﬁcity of 65.6%, and a negative predictive value of
93%. The AUC in the validation cohort was 0.72 (95% CI 0.65–0.79). Hence, the Flu-NS prediction score helped to exclude Flu-NS
Candida strains. This could improve the selection of empirical treatments for candidaemia in the future.
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p://dx.doi.org/10.1016/j.cmi.2015.02.029IntroductionCandidaemia remains a frequent cause of nosocomial blood-
stream infection worldwide and is associated with signiﬁcant
morbidity, prolonged hospital stays, increased healthcare costs
and high mortality [1,2].
The empirical treatment of this life-threatening infection also
remains a challenge for clinicians. Although ﬂuconazole hasious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Cuervo et al. Predicting ﬂuconazole non-susceptible candidaemia 684.e2typically been the preferred initial treatment, especially in
haemodynamically stable patients without previous azole
exposure [3,4], recent epidemiological studies raise concerns
about the increasing prevalence of Candida species non-
susceptible to ﬂuconazole (Flu-NS) [1,5]. Accordingly, current
guidelines have relegated ﬂuconazole to be used only as a step-
down treatment option [6,7]. However, some observational
studies suggest that this management strategy could have an as-
yet unknown ecological impact [8–10], in addition to the
obvious rise in healthcare expenses. It has therefore become
necessary to determine the current role of ﬂuconazole in the
empirical treatment of candidaemia.
We aimed to develop and validate a Flu-NS prediction score
that would be easy to use at the bedside, using only simple
clinical criteria to assess the risk factors for Flu-NS candidae-
mia. Ultimately, this tool could be useful when selecting an
empirical antifungal treatment for patients with candidaemia.Materials and methodsStudy design, setting and patients
We extracted a derivation cohort from the CANDIPOP study
(the Prospective Population Study on Candidaemia in Spain), a
prospective, multicentre, population-based surveillance pro-
gramme on candidaemia conducted in 29 hospitals in ﬁve of the
largest metropolitan areas of Spain [11]. Between April 2010
and May 2011, blood cultures positive for Candida spp. were
identiﬁed in the microbiology laboratories of participating
hospitals and reported to regional study collaborators who
collected clinical data using a standardized case report form as
described elsewhere [11]. The study was approved by the
ethics committees of each participating institution.
We created an external validation cohort that included all
adult patients diagnosed with candidaemia between January
2005 and December 2012 in six tertiary hospitals in three
countries (three in Spain, two in Argentina and one in Brazil).
Information was retrospectively collected by detailed review
of the medical records. The study was approved by the ethics
committees of the participating institutions. The same inclu-
sion and exclusion criteria were used as for the CANDIPOP
study.
Variables and deﬁnitions
The primary outcome variable was the presence of a Candida
bloodstream infection caused by a Flu-NS isolate. For the
purpose of this study, Candida strains were divided in two
groups according to MIC values obtained by CLSI procedure:
isolates fully susceptible to ﬂuconazole (Flu-S; i.e. those with an
MIC <4 mg/L) and isolates non-susceptible to ﬂuconazole (Flu-Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InNS; i.e. those with an MIC 4 mg/L in addition to Candida
krusei, Candida glabrata and Candida guilliermondii regardless of
their MIC value), which included ﬂuconazole-resistant as well as
ﬂuconazole dose-dependently susceptible isolates. The MIC
cut-off value was selected according to CLSI criteria for Candida
species-speciﬁc clinical breakpoints [12]. For species in which
breakpoints are lacking, we considered as Flu NS the non-wild-
type isolates. We recorded only nine cases of candidaemia
caused by C. guilliermondii in the derivation cohort. Among
them, more than 66% (6/9) displayed a MIC of ﬂuconazole
4 mg/L. Nevertheless, we truly believe that these isolates
should be classiﬁed as Flu-NS, as there is scarce evidence that
C. guilliermondii is a good target for therapy with ﬂuconazole. As
the aim of the score is to provide a tool to safely choose an
empirical treatment, we are persuaded that it was a cautious
approach. For those episodes in which two different Candida
spp. were recovered simultaneously in the blood culture, at
least one strain was required to meet the criteria for Flu-NS. In
a second analysis in the derivation cohort, we used the deﬁni-
tion of Flu-S and Flu-NS strains according to the non-species-
speciﬁc Candida breakpoints published in the EUCAST web-
page (http://www.eucast.org/ﬁleadmin/src/media/PDFs/
EUCAST_ﬁles/AFST/Antifungal_breakpoints_v_7.0.pdf) as pre-
viously reported [13].
Previous exposure to azoles was considered if it had
occurred in the 30 days before drawing the ﬁrst positive blood
culture. The type, dose and duration of previous antifungal
therapy were recorded. Severity of candidaemia was classiﬁed
as sepsis, severe sepsis, or septic shock at presentation ac-
cording to standard deﬁnitions [14]. To account for local
epidemiology and antifungal resistance patterns, we used a
variable that reﬂected resistance rates at the ward level in each
hospital. Wards with a prevalence of Flu-NS isolates >15%
were deﬁned as high prevalence units (HPU).
Microbiological studies
Candida isolates corresponding to episodes recorded in the
derivation cohort were processed and stored at participating
hospitals as described elsewhere [13]. Fluconazole susceptibility
testing was performed according to the CLSI M27-A3 [15] and
EUCAST (E.Def7.1 and E.Def7.2) [16,17] broth microdilution
methods. The ﬂuconazole MIC was deﬁned as the lowest drug
concentration that inhibited 50% of growth compared with the
growth control after 24 h of incubation at 35°C for all Candida
species, except for C. glabrata, which was determined after 48 h
to prevent misclassiﬁcation bias among the isolates [18]. CLSI
and EUCAST procedures were carried out at the Clinical
Microbiology Department of Gregorio Marañón Hospital and at
the Spanish National Centre for Microbiology in Madrid,
respectively, as previously reported [13].fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
TABLE 1. Demographic, clinical and microbiological
characteristics among patients included in the derivation and
external validation cohorts
Derivation
cohort
(n [ 617)
External validation
cohort (n [ 297)
Demographics
Male sex, n (%) 367 (59.5) 174 (58.6)
Age (years), median (IQR) 67.8 (54.3–77.3) 62 (50–73.5)
Length of in-hospital stay (days),
median (IQR)
20 (12–36) 15 (3–30)
High prevalence unit, n (%) 269 (43.6) 169 (56.9)
Comorbidities, n (%)
Diabetes mellitus 153 (24.8) 89 (30)
Liver disease 95 (15.4) 58 (19.5)
COPD 74 (12) 69 (23.2)
Chronic renal disease 174 (28.2) 82 (27.6)
Dialysis 42 (6.8) 24 (8.1)
Cerebrovascular disease 50 (8.1) 40 (13.5)
Active malignancy 238 (38.6) 132 (44.4)
Transplant recipienta 40 (6.5) 44 (14.8)
HIV infection 16 (2.6) 13 (4.4)
Risk factors for candidaemia, n (%)
ICU admission (at onset) 173 (28) 77 (25.9)
Central venous catheter 459 (74.6) 178 (59.9)
Total parenteral nutrition 281 (45.5) 127 (42.8)
Previous gastrointestinal surgeryb 184 (29.8) 77 (25.9)
Neutropenia (<500) 26 (4.2) 30 (10.1)
Chemotherapyb 55 (8.9) 57 (19.2)
Corticosteroid therapyb 175 (28.4) 133 (44.8)
Previous antibioticsb 471 (76.4) 260 (87.5)
Previous antifungalsb 100 (16.2) 22 (7.4)
Previous azole therapy (3 days) b 78 (12.6) 15 (5.1)
Severity, n (%)
Septic shock 94 (15.2) 85 (28.6)
Source of infection, n (%)
Primary 342 (55.4) 142 (47.8)
Catheter-related 206 (33.4) 57 (19.1)
Urological 38 (6.2) 26 (8.8)
Abdominal 25 (4.1) 21 (7.1)
Other 6 (1) 3 (1)
Microbiology
Candida species, n (%)c
C. albicans 291 (46.3) 141 (47.5)
C. parapsilosis 136 (21.7) 49 (16.5)
C. glabrata 97 (15.4) 37 (12.5)
684.e3 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIFor episodes recorded in the validation cohort, yeast iden-
tiﬁcation and in vitro antifungal activity were assessed at
participating hospitals using local routine methods. In vitro
antifungal activity was studied by a commercial microdilution
method (YeastOne®Sensitre®, TREK Diagnostic Systems Ltd,
East Grinstead, UK) or by E-test (BioMérieux SA, Paris,
France), in accordance with the manufacturer’s instructions.
Antifungal susceptibility of the isolates was classiﬁed according
to the CLSI M27-A3 document [15].
Statistical analysis
Categorical variables were compared using the chi-square or
Fisher exact tests; continuous variables were compared using
the Student’s t-test or Mann–Whitney U-test, as appropriate.
All statistical tests were two-tailed, and signiﬁcance was set at
p < 0.05.
Potential predictors of Flu-NS isolates were identiﬁed by
logistic regression analysis using the CLSI MIC clinical break-
points. To facilitate score generation and application in clinical
settings, continuous variables (e.g. days of previous azole
exposure) were transformed into binary factors using the most
discriminatory cut-off point. Statistically signiﬁcant variables in
univariate analysis were entered into a multivariate logistic
regression model. Calibration of the model was assessed by the
Hosmer–Lemeshow test. The ﬁnal regression model was
transformed into a point-based score to build the predictive
score. The logistic regression coefﬁcients for statistically sig-
niﬁcant predictors of Flu-NS isolates were rounded to integers
to assign the value of each variable. It was decided a priori that
septic shock would remain in the predictive score because it is
usually taken into account when choosing empirical therapy
using existing guidance [3].
The discriminatory power of the developed score was
evaluated by the area under the receiver operating character-
istics (ROC) curve (AUC) and the 95% CI. We selected the
best cut-off value to estimate the diagnostic sensitivity and
speciﬁcity in the validation set. The prediction score was
internally assessed with the MIC values obtained by the
EUCAST method in the CANDIPOP study and then applied to
the external validation cohort. The discrimination ability of the
score was again assessed by AUC of ROC curve analysis. Sta-
tistical analyses were performed with MICROSOFT SPSS-PC+,
version 15.0 (SPSS, Chicago, IL, USA).
C. tropicalis 52 (8.3) 40 (13.5)
C. krusei 14 (2.2) 13 (4.4)
Other 38 (6.1) 17 (5.7)
Flu-NS strains, n (%) 134 (21.7) 57 (19.2)Results
Abbreviations: COPD, chronic obstructive pulmonary disease; HIV, human
immunodeﬁciency virus; ICU, intensive care unit; IQR, interquartile range.
aThirteen haematopoietic stem cell transplants and 27 solid organ transplants in the
derivation cohort versus 17 and 27, respectively, in the validation cohort.
bWithin the preceding month.
cEleven cases of mixed candidaemia in the derivation cohort.Study population
In total, 773 episodes of candidaemia were documented in the
CANDIPOP study. Of these, we excluded patients whoClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdeclined to participate (n = 21), those with more than one
episode (n = 23), and those <16 years old (n = 112). Conse-
quently, 617 cases of candidaemia were enrolled in the deri-
vation cohort. A total of 297 cases were analysed in the
validation cohort. Table 1 shows the baseline characteristics of
patients included in both the derivation and validation cohorts.
The most frequent species isolated in both cohorts was Candida
albicans. Flu-NS accounted for 134 strains isolated in the deri-
vation cohort (21.7%) compared with 57 strains isolated in the
validation cohort (19.2%).
Score derivation
The epidemiological and clinical characteristics of the patients
with Flu-S and with Flu-NS strains in the derivation cohort areious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
TABLE 3. Independent risk factors associated with Flu-NS
candidaemia: multivariate analysis
Characteristic AOR 95% CI p-value
Malignancy 1.27 0.82–1.96 0.282
Solid organ or haematopoietic
stem cell transplant recipient
2.13 1.01–4.55 0.047
High prevalence unit 7.53 4.68–12.10 <0.001
Previous azole therapy
(3 days)a
2.04 1.16–3.62 0.014
Abbreviations: AOR, adjusted odds ratio; Flu-NS, isolates non-susceptible to
ﬂuconazole (i.e. those with an MIC 4 mg/L plus Candida krusei, Candida glabrata
and Candida guilliermondii, regardless of their MIC value).
aWithin the preceding month.
CMI Cuervo et al. Predicting ﬂuconazole non-susceptible candidaemia 684.e4compared in Table 2. Univariate analysis identiﬁed four vari-
ables that were signiﬁcantly associated with Flu-NS, including
epidemiological factors (HPU 80.6% versus 33.3% p < 0.001),
co-morbidities (malignancy: 47% versus 36.3%, p 0.024; or
previous solid organ or haematopoietic stem cell trans-
plantation: 13.4% versus 4.6%, p  0.001) and previous anti-
fungal therapy (azole therapy for at least 3 days in the previous
month 23.1 versus 9.7%, p < 0.001). The results are equivalent
for patients who received previous ﬂuconazole therapy during
>7 days or >14 days. Multivariate analysis summarized in
Table 3 shows that the independent factors associated with Flu-
NS were as follows: being a previous solid organ or haemato-
poietic stem cell transplantation recipient, hospitalization in an
HPU, and azole therapy for 3 days. Hosmer–Lemeshov
goodness-of-ﬁt of the ﬁnal model was 82%.TABLE 2. Univariate analysis of patients with Flu-NS and Flu-S
candidaemia in the derivation cohort
Flu-S
(n [ 483)
Flu-NS
(n [ 134) p-value
Demographics
Male sex, n (%) 289 (59.8) 78 (58.2) 0.735
Age (years), median (IQR) 67.4 (54.2–76.8) 69.3 (55.5–77.7) 0.490
Length of in-hospital stay (days),
median (IQR)
20 (12–37.5) 21 (8.5–34) 0.146
High prevalence unit, n (%) 161 (33.3) 108 (80.6) <0.001
Comorbidities, n (%)
Diabetes mellitus 117 (24.2) 36 (26.9) 0.531
Liver disease 68 (14.1) 27 (20.1) 0.085
COPD 53 (11) 21 (15.7) 0.139
Chronic renal disease 143 (29.6) 31 (23.1) 0.141
Dialysis 35 (7.2) 7 (5.2) 0.411
Cerebrovascular disease 40 (8.3) 10 (7.5) 0.759
Active malignancy 175 (36.3) 63 (47) 0.024
Solid organ or haematopoietic stem
cell transplant recipient
22 (4.6) 18 (13.4) <0.001
HIV infection 10 (2.1) 6 (4.5) 0.121
Risk factors for candidaemia, n (%)
ICU admission (at onset) 141 (29.1) 32 (23.9) 0.578
Central venous catheter 364 (75.4) 95 (71.4) 0.337
Total parenteral nutrition 220 (45.5) 61 (45.5) 0.996
Previous gastrointestinal surgerya 145 (30) 39 (29.1) 0.837
Neutropenia (<500) 18 (3.7) 8 (6) 0.253
Chemotherapya 39 (8.1) 16 (11.9) 0.164
Corticosteroid therapya 137 (28.4) 38 (28.4) 0.999
Previous antibioticsa 370 (76.6) 101 (75.4) 0.679
Previous antifungalsa 67 (13.9) 33 (24.8) 0.002
Previous azole therapy (3 days) a 47 (9.7) 31 (23.1) <0.001
Severity, n (%)
Septic shock 67 (13.9) 27 (20.1) 0.074
Source of infection, n (%)
Primary 268 (55.5) 74 (55.2) 0.957
Catheter-related 168 (34.8) 38 (28.4) 0.163
Urological 27 (5.6) 11 (8.2) 0.265
Abdominal 17 (3.5) 8 (6) 0.203
Other 3 (0.6) 3 (2.2) 0.120
Microbiology
Candida species, n (%)b
C. albicans 288 (58.3) 3 (2.2) <0.001
C. parapsilosis 130 (26.3) 6 (4.57) <0.001
C. glabrata 0 97 (72.3) <0.001
C. tropicalis 50 (10.1) 2 (1.5) <0.001
C. krusei 0 14 (10.4) <0.001
C. guilliermondii 0 9 (6.7) <0.001
Other 26 (5.3) 3 (2.2) 0.067
Abbreviations: Flu-NS, isolates non-susceptible to ﬂuconazole (i.e. those with an
MIC 4 mg/L plus C. krusei, C. glabrata and C. guilliermondii, regardless of their MIC
value); Flu-S, isolates fully susceptible to ﬂuconazole (i.e. those with an MIC <4 mg/
L).
aWithin the preceding month.
bEleven cases of mixed candidaemia.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InResults from the multivariate analysis were used to develop
the clinical Flu-NS prediction score. According to the regres-
sion coefﬁcients, we assigned 2 points to HPU and 1 point to
each of the other independent parameters. We also added 1
point for patients with septic shock at presentation. The
application of the score to patients enabled us to categorize
subjects into six different classes: 269 (43.6%) had 0 points, 72
(11.7%) had 1 point, 172 (27.9%) had 2 points, 85 (13.8%) had 3
points, 17 (2.8%) had 4 points and 2 (0.3%) had 5 points. The
incidence of Flu-NS by the CLSI reference procedure in these
groups was 7.1%, 6.9%, 33.7%, 45.9%, 64.7%, and 100%,
respectively. The ROC curve for the Flu-NS prediction score
showed an accuracy measured by the AUC of 0.76 (0.72–0.81)
(Fig. 1, curve A). When applied exclusively to the 26 neu-
tropenic patients of this cohort, the Flu-NS score conserved its
performance (ROC curve AUC 0.79 (0.59–0.98)). Diagnostic
sensitivity, speciﬁcity and predictive values according to
different cut-off values in the derivation cohort are shown in
Table 4. A cut-off point of 2 for the Flu-NS score had a
sensitivity of 82.1%, a speciﬁcity of 65.6% and a negative pre-
dictive value of 93% (Table 4). Using the MIC cut-off value
obtained by the EUCAST procedure to classify episodes as Flu-
NS in the same cohort, the score retained an AUC of 0.79 (95%
CI 0.76–0.83) (Fig. 1, curve B). The application of the score
when the MIC values were obtained by the EUCAST procedure
enabled us to categorize subjects into six different classes: 221
(35.9%) had 0 points, 64 (10.4%) had 1 point, 218 (35.4%) had 2
points, 93 (15.1%) had 3 points, 18 (2.9%) had 4 points and 2
(0.3%) had 5 points. The incidence of Flu-NS in these groups
was 2.7%, 3.1%, 36.2%, 46.2%, 66.7% and 100%, respectively.
External validation
The application of the score to patients in the validation cohort
enabled us to categorize them into six different classes: 96
(32.3%) had 0 points, 28 (9.4%) had 1 point, 109 (36.7%) had 2
points, 47 (15.8%) had 3 points, 15 (5%) had 4 points and 2
(0.7%) had 5 points. The incidences of Flu-NS in the validation
cohort ranged from 6% for patients without risk factors to 64%fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
FIG. 1. Receiver operating characteristics (ROC) curve for the Flu-NS score in three cohorts: (a) derivation, (b) EUCAST internal validation and (c)
external validation. Abbreviations: EUCAST, European Committee on Antimicrobial Susceptibility Testing; Flu-NS, isolates non-susceptible to ﬂu-
conazole (i.e. those with an MIC 4 mg/L plus Candida krusei, Candida glabrata and Candida guilliermondii, regardless of their MIC value).
684.e5 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIfor subjects with 4 or more points on the score, with an AUC
of 0.72 (95% CI 0.65–0.79) (Fig. 1, curve C). When applied
exclusively to the 30 neutropenic patients of this cohort, the
Flu-NS score conserved its performance (ROC curve AUC
0.71 (0.51–0.90)). Diagnostic sensitivity, speciﬁcity and pre-
dictive values according to different cut-off values in the vali-
dation cohort are also shown in Table 4.DiscussionIn the present study, we have created and validated a simple
score that can estimate the risk of Flu-NS candidaemia using
readily available clinical parameters at the bedside. Speciﬁcally,
the presence of hospitalization to an HPU before trans-
plantation, and at least 3 days of prior azole therapy as inde-
pendent predictors of Flu-NS by multivariate analysis allowed
us to create a valid prediction score. The absence of any of
these predictive factors decreased the risk of Flu-NS candi-
daemia substantially, supporting the empirical use of ﬂuconazole
as the ﬁrst antifungal agent. To our knowledge, this is the ﬁrst
investigation to have developed a clinically relevant tool to
guide empirical antifungal therapy in this setting. Interestingly,TABLE 4. Receiver operating characteristic curve cut-off values for
Cut-off point
Derivation cohort EUCAST inter
Sn Sp NPV PPV Sn Sp
‡1 85.8 51.8 92.9 33 95.8 45.6
‡2 82.1 65.6 93 39.9 94.4 58.7
‡3 38.8 89.2 84 50 39.6 88.1
‡4 9.7 98.8 79.7 68.4 9.7 98.7
5 1.5 100 78.5 100 1.4 100
Abbreviations: EUCAST, European Committee on Antimicrobial Susceptibility Testing; NPV
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthe score appears to retain its applicability when using the
EUCAST breakpoints.
Many previous studies have attempted to identify risk factors
associated with azole resistance. Some have analysed non-
albicans candidaemia as a surrogate marker of azole resistance
and found risk factors such as chemotherapy [19], solid tumour
[20] or previous surgery [21]. Other works with microbiological
conﬁrmation of resistance have described gastrointestinal sur-
gery [22] or the cumulative length of hospitalization [23] as being
relevant; however, these were single-centre studies limited to
oncological or critically ill surgical patients, respectively. Another
prospective study reported that neutropenia, chronic renal dis-
ease and previous ﬂuconazole exposure were independently
associated with such strains [24]. Previous azole therapy was
also found to be a risk factor in other works [25,26], all those
based on the old CLSI breakpoints. Furthermore, we found that
both prior antifungal therapy and its duration were independent
risk factors, a fact already demonstrated by other authors who
observed a dose-dependent relationship between ﬂuconazole
consumption and breakthrough azole-resistant candidaemia [27].
This evidence supports the guideline recommendation of
avoiding ﬂuconazole as the initial empiric therapy in those pa-
tients with previous exposure [3].the derivation and validation cohorts
nal validation External validation cohort
NPV PPV Sn Sp NPV PPV
97.3 35 87.7 39.6 93.1 25.6
97.1 41 84.2 49.6 92.9 28.4
82.7 50.4 42.1 84.4 85.8 39.3
78.2 70 17.5 97.9 83.2 66.7
76.9 100 1.8 100 80.9 100
, negative predictive value; PPV, positive predictive value; Sn, sensitivity; Sp, speciﬁcity.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
CMI Cuervo et al. Predicting ﬂuconazole non-susceptible candidaemia 684.e6In the present study, we stressed the importance of local
epidemiology in the pre-test probability of developing Flu-NS
candidaemia. We found that being hospitalized in a unit with
a Flu-NS candidaemia prevalence of 15% had the highest
weighting as a predictor in our score. In fact, data from the
CANDIPOP survey showed a great difference in the prevalence
of Flu-NS strains among the different participating cities [13].
This is clearly evident when we compare countries of northern
Europe with Latin-America [28,29], or wider comparisons as
the SENTRY Antimicrobial Surveillance Program [30]. Our
results highlight the importance of local surveillance studies.
Our multivariate analysis found that transplantation recipient
status was an independent predictor of Flu-NS candidaemia.
Previous reports on haematological neutropenic patients
receiving stem cell transplantation found similar results [31,32].
Nevertheless, information concerning solid organ trans-
plantation is conﬂicting, with some authors reporting greater
azole resistance [33] and others failing to report this association
[34]. However, these ﬁndings are difﬁcult to compare because
of differences in the design, deﬁnitions and populations used in
those studies.
To date, no evidence supports the argument that azole-
resistant strains are associated with a greater incidence of
septic shock. Despite this, the fungicidal activity of echino-
candins against most Candida species is argued to be a reason
for offering these drugs to unstable patients [3]. Further studies
are needed to validate this hypothesis. However, the addition of
septic shock to our clinical prediction score provides a safety
factor for clinicians, who usually prefer broad-spectrum
coverage in critically ill patients.
Our clinical prediction score faces physicians with quite
different settings. On the one hand, there is a patient subgroup
with low risk (score <1) in whom empirical ﬂuconazole appears
to be a safe initial treatment. On the other hand, there is a
patient subgroup with several risk factors (score 2) and a high
probability of Flu-NS candidaemia. Together with critically ill
patients, those patients warrant broad-spectrum therapy, with
ﬂuconazole reserved as a step-down option. Finally, for those
patients with 3 or more points on the Flu-NS score, the use of
an echinocandin should be mandatory because of the high risk
of Flu-NS isolates. To note, echinocandin-resistance (though
not common) may be observed in some Flu-NS isolates.
The strengths of the current study include the prospective
nature of the derivation cohort, the large number of consec-
utive patients evaluated, the comprehensive data collection, and
the multicentre design. Moreover, it is also important that
validation be provided in an international cohort, including
patients from different geographic areas. Nevertheless, the
predictive power of the score needs to be conﬁrmed in even
more diverse clinical settings to ensure its wider validity andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inreliability. The limitations of the present study include differ-
ences in MIC determination techniques between the derivation
and validation cohorts. As the MIC breakpoints are method-
speciﬁc, using the CLSI breakpoints for interpretation of the
MICs generated by Sensititre YeastOne or Etest in the valida-
tion cohort may have led to discordant results in a number of
isolates. Second, it is true that our score mostly identiﬁed Flu-
NS strains corresponding to non-albicans species, with primary
resistance or dose-dependent susceptibility to ﬂuconazole.
However, the Flu-NS score was also useful for patients with
isolates with acquired resistance to ﬂuconazole (11 isolates:
three C. albicans, six C. parapsilosis and two C. tropicalis). Among
them, more than 90% (10/11) had 2 points and more than
63% (7/11) had 3 points in the score. Third, it is certainly
possible that the rapid evolution of molecular diagnostic
methods [35] may lead to clinical tools such as this becoming
redundant; however, the availability of such techniques will
remain restricted in resource-limited settings. Finally, a major
drawback is in the nature of a prediction score that aims to
simplify a complex clinical situation. We stress that such a tool
should support, but never replace, clinical judgement.
In summary, our easy to use, simple Flu-NS prediction score
can estimate the risk of Flu-NS candidaemia using readily
available clinical parameters at the bedside. This gives physicians
a validated and reliable tool to enable the rational and safe
choice of an initial antifungal agent in the management of can-
didaemia in adult patients.Funding and AcknowledgementsMembers of the CANDIPOP Project
Belén Padilla, Patricia Muñoz, and Jesús Guinea (Hospital Gen-
eral Universitario Gregorio Marañón, Madrid); José Ramón
Paño, Julio García, and Carlos García (Hospital Universitario La
Paz, Madrid); Jesús Fortún, Pilar Martín, and Elia Gómez
(Hospital Universitario Ramón y Cajal, Madrid); Pablo Ryan and
Carolina Campelo (Hospital Infanta Leonor, Madrid); Ignacio de
los Santos and Buenaventura Buendía (Hospital Universitario La
Princesa, Madrid); Beatriz Pérez and Mercedes Alonso (Hospital
Universitario del Niño Jesús, Madrid); Francisca Sanz and José
María Aguado (Hospital Universitario “12 de Octubre”,
Madrid); Paloma Merino and Fernando González (Hospital
Clínico San Carlos, Madrid); Miguel Gorgolas and Ignacio Gadea
(Fundación Jiménez Díaz, Madrid); Juan Emilio Losa and Alberto
Delgado-Iribarren (Hospital de Alcorcón, Madrid); Antonio
Ramos, Yolanda Romero, and Isabel Sánchez (Hospital Uni-
versitario Puerta de Hierro-Majadahonda, Madrid); Oscar
Zaragoza and Manuel Cuenca-Estrella (Centro Nacional de
Microbiología, Instituto de Salud Carlos III, Majadahonda,fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
684.e7 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIMadrid); Jesús Rodríguez-Baño and Ana Isabel Suarez (Hospital
Universitario Virgen Macarena, Sevilla); Ana Loza, Ana Isabel
Aller and Estrella Martín-Mazuelos (Hospital Universitario Vir-
gen de Valme, Sevilla); Maite Ruiz and José Garnacho-Montero
(Hospital Universitario Virgen del Rocío, Sevilla); Carlos Ortiz
(Hospital Sagrado Corazón, Sevilla); Mónica Chávez and Fer-
nando L. Maroto (Hospital San Juan de Dios de Aljarafe, Sevilla);
Miguel Salavert and Javier Pemán (Hospital Universitari La Fe,
Valencia); José Blanquer and David Navarro (Hospital Clínico
Universitario de Valencia); Juan José Camarena and Rafael
Zaragoza (Hospital Universitario Dr. Peset, Valencia); Vicente
Abril and Concepción Gimeno (Consorcio Hospital General
Universitario de Valencia); Silvia Hernáez and Guillermo
Ezpeleta (Hospital de Basurto, Bilbao); Elena Bereciartua, José
L. Hernández and Miguel Montejo (Hospital Universitario de
Cruces, Bilbao); Rosa Ana Rivas and Rafael Ayarza (Hospital de
Galdakano, Bilbao); Ana Mª Planes, Isabel Ruiz-Camps, and
Benito Almirante (Hospital Universitari Vall d’Hebron, Barce-
lona); José Mensa and Manel Almela (Hospital Clínic-IDIBAPS,
Barcelona); Mercè Gurgui and Ferran Sánchez-Reus (Hospital
Universitari de Sant Pau i Santa Creu, Barcelona); Joaquín
Martínez-Montauti and Montserrat Sierra (Hospital de Barce-
lona, Barcelona); Juan Pablo Horcajada, Luisa Sorli, and Julià
Gómez (Hospital del Mar, Barcelona); Amadeu Gené and Mireia
Urrea (Hospital Sant Joan de Déu, Esplugues de Llobregat,
Barcelona).
Study collaborators
Maricela Valerio, Mario Fernández-Ruiz, Ana Díaz-Martín,
Francesc Puchades, Alessandra Mularoni and Mireia Puig-
Asensio.
Members of the validation cohort
Guillermo Cuervo, Carolina Garcia-Vidal, Joseﬁna Ayats, Car-
lota Gudiol and Jordi Carratalà (Hospital Universitari de Bell-
vitge, IDIBELL, Barcelona, Spain), Marcio Nucci (University
Hospital, Universidade Federal do Rio de Janeiro, Rio de
Janeiro, Brazil), Mora Obed (Hospital “Dr. Rodolfo Rossi”, La
Plata, Argentina) and Adriana Manzur (Hospital “Dr. Guillermo
Rawson”, San Juan, Argentina).
Funding
The CANDIPOP study was supported by research grants from
Gilead, Merck Sharp & Dohme (MSD), Astellas and Pﬁzer and
by funding from Fundación SEIMC-GESIDA and Ministerio de
Economía y Competitividad, Instituto de Salud Carlos III, co-
ﬁnanced by the European Development Regional Fund ‘A
way to achieve Europe’. ERDF, Spanish Network were not
involved in the preparation of the manuscript. The validation
cohort study was supported by research grants from theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectMinisterio de Sanidad y Consumo, Instituto de Salud Carlos III
[FIS 10/01318], ESCMID Research grant 2013 and Ministerio
de Ciencia e Innovación, Instituto de Salud Carlos III, and co-
ﬁnanced by the European Development Regional Fund ‘A way
to achieve Europe’ ERDF, Spanish Network for the Research
in Infectious Diseases [REIPI RD06/0008] and by a research
grant of Astellas. Dr Garcia-Vidal is the recipient of a Juan de la
Cierva research grant from the Instituto de Salud Carlos III,
Madrid, Spain. Dr Jesús Guinea is the recipient of a Miguel
Servet contract (MS09/00055) from the Instituto de Salud
Carlos III, Madrid, Spain.Transparency declarationCG-V has received grant support from Astellas and the Insti-
tuto de Salud Carlos III, and she has received honoraria for
talks on behalf of Pﬁzer, Merck Sharp and Dohme and Astellas.
MF-R has received honoraria for talks on behalf of Pﬁzer. JP has
received grant support from Astellas Pharma, Gilead Sciences,
MSD and Pﬁzer, and has received honoraria for talks on behalf
of Astellas Pharma, Gilead Sciences, MSD and Pﬁzer. MN has
received grant support from MSD and Pﬁzer; has been an
advisor/consultant to MSD, Pﬁzer, Gilead and Astellas and has
received honoraria for talks on behalf of MSD, Pﬁzer, Gilead
and Astellas. JMA has received grant support from Astellas
Pharma, Gilead Sciences, MSD, Pﬁzer, Instituto de Salud Carlos
III (Spanish Ministry of Economy and Competitiveness) and the
Mutua Madrileña Foundation; has been an advisor/consultant
to Astellas Pharma, Gilead Sciences, MSD and Pﬁzer; and has
received honoraria for talks on behalf of Gilead Sciences, MSD,
Pﬁzer and Astellas Pharma. BA has received grant support
from Gilead Sciences, Pﬁzer and the Instituto de Salud Carlos
III, and he has received honoraria for talks on behalf of Gilead
Sciences, Merck Sharp and Dohme, Pﬁzer, Astellas and
Novartis. The remaining authors declare no conﬂict of
interest.Ethics approvalThis observational study was conducted in accordance with the
Declaration of Helsinki and was approved by the Institutional
Review Board of the Comité Ético de Investigación Clínica of
each participating hospital. To protect personal privacy, iden-
tifying information in the electronic database was encrypted for
each patient. Informed consent was waived by the Clinical
Research Ethics Committee for the validation cohort because
no intervention was involved and no patient-identifying infor-
mation was included.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
CMI Cuervo et al. Predicting ﬂuconazole non-susceptible candidaemia 684.e8References[1] Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ,
Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019
patients: data from the prospective antifungal therapy alliance registry.
Clin Infect Dis 2009;48:1695–703.
[2] Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S,
et al. Excess mortality, hospital stay, and cost due to candidemia: a
case-control study using data from population-based candidemia sur-
veillance. Infect Control Hosp Epidemiol 2005;26:540–7.
[3] Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF,
Edwards JE, et al. Clinical practice guidelines for the management of
candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis 2009;48:503–35.
[4] Karthaus M, Rüping MJGT, Cornely OA, Steinbach A, Groll AH, Lass-
Flörl C, et al.Current issues in the clinicalmanagement of invasiveCandida
infections – the AGIHO, DMykG, ÖGMM and PEG web-based survey
and expert consensus conference 2009. Mycoses 2011;54:e546–56.
[5] Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P,
Knudsen JD, et al. Epidemiological changes with potential implication
for antifungal prescription recommendations for fungaemia: data from
a nationwide fungaemia surveillance programme. Clin Microbiol Infect
2013;19:E343–53.
[6] Cornely O a, Bassetti M, Calandra T, Garbino J, Kullberg BJ,
Lortholary O, et al. ESCMID* guideline for the diagnosis and man-
agement of Candida diseases 2012: non-neutropenic adult patients. Clin
Microbiol Infect 2012;18(Suppl. 7):19–37.
[7] Ullmann a J, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-
Akdagli S, et al. ESCMID* guideline for the diagnosis and management
of Candida diseases 2012: adults with haematological malignancies and
after haematopoietic stem cell transplantation (HCT). Clin Microbiol
Infect 2012;18(Suppl. 7):53–67.
[8] Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-
resistant Candida tropicalis strains causing breakthrough fungemia in
patients at high risk for hematologic malignancies. Antimicrob Agents
Chemother 2008;52:4181–3.
[9] Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F,
Cassaing S, Baixench M-T, et al. Candida spp. with acquired echino-
candin resistance, France, 2004–2010. Candida spp. Emerg Infect Dis
2012;18:86–90.
[10] Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant
Candida glabrata: risk factors and outcomes in patients with candide-
mia. Clin Infect Dis 2014;59:819–25.
[11] Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O,
Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for
early and late mortality in Candida bloodstream infections: a popula-
tion-based surveillance in Spain. Clin Microbiol Infect 2014;20:
O245–54.
[12] Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of
Candida spp. by use of Clinical and Laboratory Standards Institute
broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012;50:
2846–56.
[13] Guinea J, Zaragoza Ó, Escribano P, Martín-Mazuelos E, Pemán J, Sán-
chez-Reus F, et al. Molecular identiﬁcation and antifungal susceptibility
of yeast isolates causing fungemia collected in a population-based study
in Spain in 2010 and 2011. Antimicrob Agents Chemother 2014;58:
1529–37.
[14] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Deﬁnitions
Conference. Crit Care Med 2003;31:1250–6.
[15] CLSI. Reference method for broth Dilution antifungal susceptibility
testing of yeasts; approved standard. 3rd ed. Wayne, PA: Clinical and
Laboratory Standards Institute; 2008.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and In[16] EUCAST deﬁnitive document EDef 7.1: method for the determination
of broth dilution MICs of antifungal agents for fermentative yeasts. Clin
Microbiol Infect 2008;14:398–405.
[17] Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W. EUCAST
technical note on the EUCAST deﬁnitive document EDef 7.2: method
for the determination of broth dilution minimum inhibitory concen-
trations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin
Microbiol Infect 2012;18:E246–7.
[18] Ostrosky-Zeichner L, Rex JH, Pfaller MA, Diekema DJ, Alexander BD,
Andes D, et al. Rationale for reading ﬂuconazole MICs at 24 hours
rather than 48 hours when testing Candida spp. by the CLSI M27-A2
standard method. Antimicrob Agents Chemother 2008;52:4175–7.
[19] Shigemura K, Osawa K, Jikimoto T, Yoshida H, Hayama B, Ohji G,
et al. Comparison of the clinical risk factors between Candida albicans
and Candida non-albicans species for bloodstream infection. J Antibiot
(Tokyo) 2014;67:311–4.
[20] Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and
outcomes of Candida albicans versus non-albicans candidemia in non-
neutropenic patients. Ann Pharmacother 2007;41:568–73.
[21] Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, et al.
Candidemia in nonneutropenic critically ill patients: risk factors for
non-albicans Candida spp. Crit Care Med 2008;36:2034–9.
[22] Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH,
et al. Candidaemia in adult cancer patients: risks for ﬂuconazole-
resistant isolates and death. J Antimicrob Chemother 2010;65:
1042–51.
[23] Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E,
Manolakaki D, Coleman JJ, et al. The effect of cumulative length of
hospital stay on the antifungal resistance of Candida strains isolated
from critically ill surgical patients. Mycopathologia 2011;171:85–91.
[24] Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de
Pipaón M, Hernández-Caballero C, Aznar-Martín J, et al. Risk factors
for ﬂuconazole-resistant candidemia. Antimicrob Agents Chemother
2010;54:3149–54.
[25] Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al.
Impact of prior inappropriate ﬂuconazole dosing on isolation of ﬂu-
conazole-nonsusceptible Candida species in hospitalized patients with
candidemia. Antimicrob Agents Chemother 2012;56:3239–43.
[26] Tumbarello M, Posteraro B, Trecarichi EM, Sanguinetti M. Fluconazole
use as an important risk factor in the emergence of ﬂuconazole-
resistant Candida glabrata fungemia. Arch Intern Med 2009;169:
1444–5. author reply 1445.
[27] Clancy CJ, Staley B, Nguyen MH. In vitro susceptibility of breakthrough
Candida bloodstream isolates correlates with daily and cumulative
doses of ﬂuconazole. Antimicrob Agents Chemother 2006;50:3496–8.
[28] Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK,
Kjaeldgaard P, et al. National surveillance of fungemia in Denmark
(2004 to 2009). J Clin Microbiol 2011;49:325–34.
[29] Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN,
Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a
laboratory-based survey. PLoS One 2013;8:e59373.
[30] Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic
variations in species distribution and echinocandin and azole antifungal
resistance rates among Candida bloodstream infection isolates: report
from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).
J Clin Microbiol 2011;49:396–9.
[31] Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic
blood and marrow transplant recipients: evolution of risk factors after
the adoption of prophylactic ﬂuconazole. J Infect Dis 2000;181:
309–16.
[32] Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M,
Voulgarelis M, et al. A prospective, cohort, multicentre study of can-
didaemia in hospitalized adult patients with haematological malig-
nancies. Clin Microbiol Infect 2014;20:O50–7.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
684.e9 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMI[33] Raghuram A, Restrepo A, Safadjou S, Cooley J, Orloff M, Hardy D,
et al. Invasive fungal infections following liver transplantation: inci-
dence, risk factors, survival, and impact of ﬂuconazole-resistant
Candida parapsilosis (2003–2007). Liver Transpl 2012;18:1100–9.
[34] Van Hal SJ, Marriott DJE, Chen SCA, Nguyen Q, Sorrell TC, Ellis DH,
et al. Candidemia following solid organ transplantation in the era ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectantifungal prophylaxis: the Australian experience. Transpl Infect Dis
2009;11:122–7.
[35] Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG,
et al. Performance of Candida real-time polymerase chain reaction,
β-D-glucan assay, and blood cultures in the diagnosis of invasive
candidiasis. Clin Infect Dis 2012;54:1240–8.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e1–684.e9
